key: cord-0792157-xdsc42oj authors: Errecalde, J.; Lifschitz, A.; Vecchioli, G.; Ceballos, L.; Errecalde, F.; Ballent, M.; Marín, G.; Daniele, M.; Turic, E.; Spitzer, E.; Toneguzzo, F.; Gold, S.; Krolewiecki, A.; Alvarez, L.; Lanusse, C. title: Ivermectin repurposing for COVID-19 therapy: Safety and pharmacokinetic assessment of a novel nasal spray formulation in a pig model date: 2020-10-24 journal: bioRxiv DOI: 10.1101/2020.10.23.352831 sha: 4d7528bb714ff0c2d10bd316d02238b216578d07 doc_id: 792157 cord_uid: xdsc42oj High ivermectin (IVM) concentrations suppress in vitro SARS-CoV-2 replication. Nasal IVM spray (N-IVM-spray) administration may contribute to attaining high drug concentrations in nasopharyngeal (NP) tissue, a primary site of virus entrance/replication. The safety and pharmacokinetic performance of a new N-IVM spray formulation in a piglet model were assessed. Crossbred piglets (10–12 kg) were treated with either one or two (12 h apart) doses of N-IVM-spray (2 mg, 1 puff/nostril) or orally (0.2 mg/kg). The overall safety of N-IVM-spray was assessed (clinical, haematological, serum biochemical determinations), and histopathology evaluation of the application site tissues performed. The IVM concentration profiles measured in plasma and respiratory tract tissues (nasopharynx and lungs) after the nasal spray treatment (one and two applications) were compared with those achieved after the oral administration. Animals tolerated well the novel N–IVM-spray formulation. No local/systemic adverse events were observed. After nasal administration, the highest IVM concentrations were measured in NP and lung tissues. Significant increases in IVM concentration profiles in both NP-tissue and lungs were observed after the 2-dose nasal administrations. The nasal/oral IVM concentration ratios in NP and lung tissues (at 6 h post-dose) markedely increased by repeating the spray application. The fast attainment of high and persistent IVM concentrations in NP tissue is the main advantage of the nasal over the oral route. These original results are encouraging to support the undertaking of further clinical trials to evaluate the safety/efficacy of the nasal IVM spray application in the treatment and/or prevention of COVID-19. there is now available information from a randomized clinical trial on IVM antiviral activity in 68 SARS-CoV-2 infected patients (11) .The mechanism by which IVM inhibits SARS-COV-2, 69 seems to be the same described for other RNA viruses, i.e. inhibition of transport across the 70 nuclear membrane mediated by importin α/β1 heterodimer, carrier of some viral molecules 71 indispensable for the replication process (12, 13). Only limited information on inhaled IVM in rats is available (17) and to the best of our 93 knowledge, this is the first time that a nasal IVM spray formulation is developed and its Objectives and study design 135 The main goals of the work described here were: 1) to assess the safety of the N-IVM spray 136 in single and double dose administration to healthy piglets, and 2) to determine the IVM 137 concentration profiles in NP tissue, lung tissue and plasma, at different times after its 138 intranasal spray (one and two applications) and oral administration. The animal phase of the study was conducted at an intensive pig farming establishment ("El Table I . The N-IVM spray was well tolerated after either one or two applications to the Animal Table II . Table III . Table IV . Using the oral tablet administration as a reference, the relationship between IVM Table II . Haematological and serum biochemical range values obtained in experimental 1 5 pigs before and after the treatment with either one or two doses of the N-IVM spray 1 6 formulation. Ivermectin and Malaria-Putting an Elderly Drug to a New Test Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant 382 clinical strains Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; 385 protection against all 4 DENV serotypes by the inhibitor IVM IVM exhibits potent antimitotic activity The multitargeted drug IVM: 389 from an antiparasitic agent to a repositioned cancer drug Anti-parasitic drug IVM 391 exhibits potent anticancer activity against gemcitabine-resistant cholangiocarcinoma in vitro The broad spectrum antiviral IVM targets the host nuclear transport importin α/β1 395 heterodimer Nuclear import and export inhibitors alter capsid protein distribution in 398 mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication Influenza A viruses escape from MxA 402 restriction at the expense of efficient nuclear vRNP import The FDA-approved Drug IVM 404 inhibits the replication of SARS-CoV-2 in vitro Ivermectin Effect on SARS-CoV-2 Replication in Patients with 406 COVID-19 An AlphaScreen(R)-based 409 assay for high-throughput screening for specific inhibitors of nuclear import IVM is a specific 412 inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and 413 dengue virus Virological assessment of hospilatalized 417 patients vith COVID-2019 Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle Development of a 422 minimal physiologically-based pharmacokinetic model to simulate lung exposure in humans 423 following oral administration of Ivermectin for COVID-19 drug repurposing Study on the subacute inhalation 426 toxicity of ivermectin TC in rats 429 19. VICH Guideline 9. Veterinary Medicines and Information Technology Unit /595/98-FINAL. The European Agency for the Evaluaion of Medicinal Products 431 (EMEA) Guidelines for human handling, 433 transport and slaughter of livestock. Food and Agriculture Organisation The porcine biomodel in translational 439 medical research: From biomodel to human lung transplantation Pharmacokinetics and 441 bioequivalence in the pig of two ivermectin feed formulations Treatment of pigs with endectocides as a 445 complementary tool for combating malaria transmission by Anopheles farauti (s.s The authors wish to thank all those collaborators (at each of the involved institutions) who 349 have anonymously contributed with the execution of the work reported here.